Context Therapeutics is trading 10.87% lower at $0.21 in pre-market, with the decline’s cause unconfirmed.
- Its investor-relations press-release page lists September 9 as its latest announcement; no October 23 release is shown.
- Available evidence establishes neither a company-specific catalyst nor a clear broader-market explanation. Pre-market trading is early, and no volume information was provided.